09:17 AM EDT, 10/08/2025 (MT Newswires) -- Astria Therapeutics ( ATXS ) said Wednesday it has started a phase 3 long-term trial of navenibart in patients with hereditary angioedema.

The trial will be split over two parts and participants will receive navenibart in a fixed dosing regimen for at least six months during the first part, the company said.

Eligible participants may continue into the trial's second part, where all participants will receive navenibart either once every three months or once every six months based on their dosing needs, it said.

Shares of the company were up 4.4% in recent Wednesday premarket activity.